HEPATO CELLULAR CARCINOMA (HCC)
Clinical trials for HEPATO CELLULAR CARCINOMA (HCC) explained in plain language.
Never miss a new study
Get alerted when new HEPATO CELLULAR CARCINOMA (HCC) trials appear
Sign up with your email to follow new studies for HEPATO CELLULAR CARCINOMA (HCC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to slash liver cancer return after surgery
Disease control Not yet recruitingThis study tests whether giving a combination of local treatments (TACE or ablation) and immunotherapy drugs before surgery can lower the chance of liver cancer coming back. It involves 105 adults with resectable liver cancer at intermediate-to-high risk of recurrence. The goal i…
Matched conditions: HEPATO CELLULAR CARCINOMA (HCC)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 26, 2026 07:53 UTC
-
New combo therapy targets tough liver and kidney cancers
Disease control Not yet recruitingThis study tests a new drug called WGI-0301 combined with the immunotherapy nivolumab in people with advanced liver or kidney cancer. The goal is to see if the combination is safe, how the body handles it, and whether it can shrink tumors. About 230 adults aged 18-75 will take pa…
Matched conditions: HEPATO CELLULAR CARCINOMA (HCC)
Phase: PHASE2 • Sponsor: Zhejiang Haichang Biotech Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 07:51 UTC
-
Can Pre-Surgery immunotherapy stop liver cancer from coming back?
Disease control Not yet recruitingThis study tests whether giving an immunotherapy drug (atezolizumab) before surgery can help the immune system fight liver cancer more effectively. About 30 adults with early-stage liver cancer will receive the drug before their tumor is removed. The goal is to see if this approa…
Matched conditions: HEPATO CELLULAR CARCINOMA (HCC)
Phase: PHASE3 • Sponsor: University of Geneva, Switzerland • Aim: Disease control
Last updated May 15, 2026 11:55 UTC